Date: 22 Apr 2026
Continuous Glucose Monitoring (CGM) is transforming the way diabetes is managed, and its impact is especially profound during pregnancy. Much like ambulatory blood pressure monitoring or Holter monitoring used in cardiology, CGM provides a continuous, real-time view of glucose levels throughout the day and night. This offers clinicians and patients a depth of insight that traditional blood glucose logs simply cannot match. Instead of relying on a few isolated readings, CGM captures trends, fluctuations, and hidden patterns — helping in making more precise and timely treatment decisions.
Maintaining strict glycemic control during pregnancy is not just recommended — it is critical. The target glucose levels during pregnancy are significantly tighter than usual, with fasting glucose expected to stay below 90 mg/dL and post-meal levels below 120 mg/dL after two hours. These targets are based on strong clinical evidence, as poor glycemic control can lead to serious complications for both the mother and the baby.
In women with Type 1 diabetes, the risk of macrosomia — where the baby grows excessively large — still affects more than 50–60% of pregnancies despite modern advancements. Alongside this, hypoglycemia remains a persistent challenge, often difficult to predict and manage. Traditional self-monitoring of blood glucose (SMBG), while considered the gold standard, often falls short in real-world scenarios. Patients frequently struggle with maintaining accurate logbooks, leading to gaps in data and increased anxiety. This is where CGM provides a significant advantage by offering continuous, reliable monitoring without the burden of manual tracking.
A CGM system consists of a small sensor placed under the skin that continuously measures interstitial glucose levels. This data is transmitted to a receiver or a smartphone application, allowing both patients and healthcare providers to monitor glucose trends in real time. Unlike traditional monitoring methods, CGM provides a comprehensive picture of glucose behavior, including key metrics such as mean glucose levels, time in range (TIR), time spent above range, and time below range.
For pregnant women with Type 1 diabetes, clinical guidelines recommend spending more than 70% of the day within the target glucose range of 63–140 mg/dL, with less than 25% above and less than 5% below this range. These percentages are not just numbers — they directly impact outcomes. Even a 5% improvement in time in range, which equates to roughly one additional hour per day within the target range, has been associated with lower risks of large-for-gestational-age babies, reduced neonatal hypoglycemia, and fewer NICU admissions. This highlights how small improvements can lead to meaningful clinical benefits.
One of the most significant studies in this area is the CONCEPT trial, a multinational randomized controlled study conducted across 31 centers in seven countries. This study evaluated pregnant women with Type 1 diabetes as well as those planning pregnancy, comparing outcomes between those using real-time CGM combined with SMBG and those relying on SMBG alone. The findings were compelling — patients using CGM showed better HbA1c levels at both 24 and 34 weeks of pregnancy.
More importantly, the time spent within the target glucose range was significantly higher in the CGM group — averaging 16.3 hours per day compared to 14.6 hours in the SMBG-only group. This difference translated into improved neonatal outcomes, reinforcing the clinical value of CGM. Additional research combining data from the CONCEPT trial and a Swedish study involving 386 women revealed that differences in glucose patterns between women who delivered large babies and those who did not could be identified as early as 10 weeks into pregnancy. This emphasizes the importance of early monitoring and intervention.
The data also provided valuable insights into how glucose patterns change during pregnancy. Hypoglycemia tends to be more common in the first trimester, while post-meal glucose spikes become more prominent in later stages. Understanding these patterns allows clinicians to personalize treatment strategies, adjusting diet and insulin therapy more effectively.
A compelling example comes from a 29-year-old woman with a 13-year history of Type 1 diabetes who presented at 8 weeks of pregnancy with poorly controlled glucose levels and an HbA1c of 9.7%. She was started on a structured insulin regimen along with intermittently scanned CGM. Initially, her time in range was just 25%, indicating significant instability.
With consistent monitoring, dose adjustments, and patient education, her condition improved steadily. Her time in range increased to 57%, then 67%, while her HbA1c dropped to 6.9%. She was later transitioned to an advanced hybrid closed-loop insulin pump system that worked in sync with CGM to automatically adjust insulin delivery. Eventually, her time in range reached an impressive 85–86%, with minimal fluctuations and no hypoglycemic episodes. She successfully delivered a healthy baby, demonstrating the real-world impact of CGM-driven care.
While the benefits of CGM are well established in Type 1 diabetes, its role in Type 2 diabetes and gestational diabetes (GDM) is still evolving. Some studies, such as the GLUCOMS trial, have shown that retrospective CGM — where patients cannot see their data in real time — may not significantly improve outcomes. However, consistent findings across research indicate that outcomes improve when CGM devices are used regularly, particularly when worn for more than 50% of the time.
Emerging research is also exploring the potential of CGM as a diagnostic tool. A recent study found that women who later developed gestational diabetes had higher glucose levels and spent more time above target ranges even before 17 weeks of pregnancy. This suggests that CGM could help identify high-risk individuals much earlier than current methods. Additionally, studies in India have highlighted that real-time CGM enables more timely and data-driven treatment adjustments, making it a valuable tool in managing GDM effectively.
Importantly, CGM and insulin pump technologies have also been shown to be safe and effective during labor and delivery, including caesarean sections. This removes a significant barrier that previously limited their use in clinical practice.
Continuous Glucose Monitoring is no longer a futuristic concept in obstetric diabetes care — it is rapidly becoming a clinical necessity, particularly for managing Type 1 diabetes during pregnancy. For gestational and Type 2 diabetes, the evidence is growing stronger with each study. The ability to access continuous, real-time data allows for more informed decisions, better treatment adjustments, and ultimately improved outcomes for both mother and baby.
As healthcare continues to evolve toward precision medicine, CGM stands out as a powerful tool that bridges the gap between data and decision-making. Better monitoring leads to better control, and better control leads to healthier pregnancies and safer deliveries.